Why the study?
What is the long-term cardiotoxicity profile of trastuzumab in patients with early breast cancer?
What is the long-term cardiotoxicity profile of trastuzumab in patients with early breast cancer?
Real-world long-term cardiotoxicity of trastuzumab in early breast cancer appears less favorable than reported in major clinical trials, highlighting the need for risk-reduction strategies in high-risk women.
Answers are grounded in this paper and cite their sources.
May warrant closer real-world cardiotoxicity surveillance than trials suggest; leaves open optimal subgroup-specific prevention strategies.
Cardiotoxicity of trastuzumab varies considerably across subgroups of patients. The long-term safety profile was less favorable than in the largest clinical trial. Strategies to reduce cardiotoxicity in high-risk women should be investigated.
No takes yet. Share an insight, caveat, or question.
Bonifazi et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: